Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts have given Inovio Pharmaceuticals, Inc. a **"Moderate Buy"** rating, with three analysts recommending a hold and three recommending a buy, and an average price target of **$8.80** for the coming year.
• Institutional investors have shown increased interest, with several firms like **Nomura Holdings** and **Jane Street Group** significantly boosting their stakes in the company during recent quarters.
• Inovio Pharmaceuticals recently reported earnings of **($0.61) per share**, slightly exceeding analyst expectations of **($0.63)**, but is projected to post **-4.23 EPS** for the current fiscal year.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $8.80.

A number of equities analysts recently weighed in on the stock. Piper Sandler assumed coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an "overweight" rating and a $5.00 target price for the company. Zacks Research lowered shares of Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Wall Street Zen cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Finally, HC Wainwright restated a "neutral" rating and set a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Thursday, August 14th.

Institutional Trading of Inovio Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INO. Jane Street Group LLC raised its position in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company's stock valued at $81,000 after purchasing an additional 27,329 shares during the period. Qube Research & Technologies Ltd purchased a new position in Inovio Pharmaceuticals in the second quarter worth approximately $234,000. Catalyst Funds Management Pty Ltd acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $35,000. Bank of Montreal Can boosted its position in shares of Inovio Pharmaceuticals by 23.7% in the 2nd quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company's stock worth $118,000 after buying an additional 11,110 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $86,000. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Trading Up 8.3%

INO stock traded up $0.19 during trading on Monday, reaching $2.49. 838,903 shares of the stock were exchanged, compared to its average volume of 1,999,554. The company has a market capitalization of $132.32 million, a P/E ratio of -0.95 and a beta of 1.61. The stock has a 50 day simple moving average of $1.93 and a 200-day simple moving average of $1.89. Inovio Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $6.45.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.02. Equities analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.